Results 251 to 260 of about 803,197 (352)
Characterization of the role of putative <i>Aeromonas caviae</i>-specific virulence factor, <i>flgB,</i> in virulence and host-pathogen interactions. [PDF]
Hritzo BA, Michalski JM, Rasko DA.
europepmc +1 more source
FPD‐GELNs co‐deliver Su and bioactive components. This active‐passive dual‐targeting strategy suppresses the progression of RCC through the following mechanisms: 1) inhibition of the PI3K‐Akt signaling pathway; 2) downregulation of ABCB1/P‐gp to enhance the chemosensitivity of RCC to Su; and 3) reprogramming of macrophages toward M1 polarization and ...
Haoyu Xu +8 more
wiley +1 more source
Autophagy in mycobacterial infections: molecular mechanisms, host-pathogen interactions, and therapeutic opportunities. [PDF]
Li J, Feng H, Chen D, Zhang H, Liao Y.
europepmc +1 more source
HLA-E: exploiting pathogen-host interactions for vaccine development [PDF]
Hannah Sharpe +3 more
openalex +1 more source
Tumor evolution in lung adenocarcinoma is shaped by genetic alterations and spatial immune dynamics. By integrating whole‐exome sequencing, imaging mass cytometry, and spatial transcriptomics across two mouse models, this study reveals how mutational burden, immune infiltration, and cell–state interactions evolve during early and late carcinogenesis ...
Bo Zhu +34 more
wiley +1 more source
Metabolomic profiling of host-pathogen interactions: differential effects of Gram-positive and Gram-negative bacterial secretomes on THP-1 macrophage metabolism. [PDF]
Abuawad A +4 more
europepmc +1 more source
Yash Srivastav1, Shankar Gavaroji2, Tanmay Ghosh3, Deepika Singh4, Rohini Armo5, Vivek6, Harish Nath7, Swapnil Dattatray Darade8, Varaganti Sai Chitra Prathyusha*9
openalex +1 more source
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia +14 more
wiley +1 more source

